I think the float price was more like $2.40. But as it has been split into 3 this works out at a present price of 80c approx. Having an honest and smart CEO like McNamee was a good factor also. I'd love to find another one but as you say where?
True. I was upset when the Libs cut funding but Labor are proving even worse.
CFU was an Australian invention but when they presented it to the Parlimentary party they couldn't understand the potential or even really understand how it worked. The minutes of the meeting would make you cry. We need men like Monash in parliment. Too many lawyers.
Do you have the minutes to the meeting by any chance?
Those government organisations need a team of commercialisation specialists, ditto the universities. Researchers and politicians aren't going to take your product to market.
Usual stuff so far from CSL. Profit up by 24%, R&D $US190m up 14%, Dividend $US50c ($AU48.66c unfranked) up 33%.
Looks like people took the dividend on the fake out!
Wish I had been watching, would have gone short at 2% rise on that dinosaur news.
When do they stop that aggressive buying of their own shares anyway?
Looking for another opportunity.
i sold some at $40 seeing as they hadn't been that high for years, the some more at $45.55. If they reach $50 I am selling the lot, but I already regret selling at $40 :-( Will I regret selling at $50?
UBS rates CSL as Buy (1) - CSL's result exceeded consensus and guidance, which the broker's suggests is quite an achievement for a first-year CEO. Highlights included 17% second half gains for IVIG with no price rises and the pre-sale of all of CSL's FY15 flu vaccine production. The broker suggests volume-driven gains represent market share gains and that momentum will continue into FY15.
The broker has not increased forecasts, other than to account for a new buyback, but has increased its PE assumption in raising its target to $85 from $80. Buy retained.
Target price is $85.00 Current Price is $67.24 Difference: $17.76 If CSL meets the UBS target it will return approximately 26% (excluding dividends, fees and charges).
The company's fiscal year ends in June. UBS forecasts a full year FY15 dividend of 140.02 cents and EPS of 340.82 cents . At the last closing share price the estimated dividend yield is 2.08%.
Indeed.
From UBS via FN Arena:
I looked closely at adding to my position when CSL's share price went as low as $64/share but then was distracted by work-a-day pressures and missed the boat. It's shot up to almost $69/share this morning.
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?